Camurus: Brixadi bounced back; optionality provided in the incretin sp...

Camurus' Q2 earnings main takeaway was Brixadi rebounding sharply (+32% QoQ at CER), signalling that earlier US market headwinds - insurance renewals, CJS funding delays and destocking - have largely resolved. Prescription data (TRx) for Q2 was 2.1x YoY, supporting our estimate of c. 51k patients o

Heads-up for Q2 report 22 July

Camurus Q2: Brixadi renewed growth, Buvidal slowed

Camurus reported its Q2 2025 results, highlighted by renewed growth for Brixadi in the US at CER (still impacted by FX headwinds), a slowing of Buvidal and a beat on profitability. Total revenues came in at SEK676m (c. +6.8% vs css) and PBT at SEK307m (+14,6% vs css), impacted by the USD12m upfront

Lowering growth and capex?

Profit waring: Q2 operating result EUR -25m

Camurus: Oczyesa gains EU approval for Acromegaly

Oclaiz/Oczyesa (Octreotide LAI, somatostatin analogue SSA) gained EU approval for Acromegaly - largely expected following the positive CHMP opinion in April'25. While the commercial potential in EU is rather limited for the indication (we estimate USD170m in total peak sales, with the US accounting

May: Pulp shipments -1.7% y-o-y

More value than momentum, except for wood

Q2 preview

Camurus: CAM2029 Ph2/3 in PLD met primary endpoint, follow up Ph3 TBD

Camurus reported topline data from its phase 2/3 POSITANO study (n=71) evaluating CAM2029 in PLD which met the primary endpoint showing stat. sig. relative reduction of the liver volume (htTLV) from baseline to week 53 of 4.3% (p=0.044) vs pbo, with corresponding relative reduction in total liver c

Norway: Best ideas Q2'25

Camurus: Signs USD870m deal with Lilly for LAI incretins

Camurus signed a USD870m deal with Eli Lilly, licensing its FluidCrystal technology for up to four long-acting injectable (LAI) incretin candidates. The upfront, development and regulatory milestones of USD290, combined with USD580m in sales milestones and tiered mid-single digit royalties, further

Apr: Pulp shipments +2% y-o-y

Large forest deal at EV/EBITDA 36-60x

Mar: Pulp shipments +7% y-o-y

Camurus Q1: Beat on profitability, Buvidal/Brixadi momentum preserved

Camurus reported its Q1'25 results, with topline revenues of SEK558m (c. -6% vs css, primarily due to FX), and a beat on profitability with PBT coming in at SEK254m (c. +20% vs css). Buvidal maintained its growth momentum in Q1 with 3,000 new patients on treatment (vs. 4,000 in Q4, but consistent w

Norsk Hydro (Sell, TP: NOK55.00) - Q1 shipments delayed to Q2

Norsk Hydro’s Q1 results fell somewhat short of market expectations (EBITDA 4% below consensus) and it cut its Extrusions guidance. A large share of the miss appears to reflect late shipments in the bauxite and alumina (B&A) segment following heavy rainfall, which should mean higher volumes in Q2. We have made only minor changes (-1–0%) to our 2026–2027e EPS. We continue to see downside risk to aluminium prices, and reiterate our SELL and NOK55 target price.

Q1 delivered, Q2 looks tougher

Muted estimate changes

Q1 above, Q2 likely worse

Beat on clean EBIT. Higher deliveries and production on paperboard.